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http:WHAT THIS PAPER ADDS
Because of acceptable durability, low operative mortality, device improvement, and increased operator expe-
rience, stent-supported endovascular therapy is widely used and considered ﬁrst-line therapy for patients with
aorto-iliac occlusive disease in clinical practice. In light of the association between perioperative complications
(POC) occurrence and clinical outcomes documented in this study, stratiﬁcation based on number of risk factors
for POC occurrence plays an important role in decision making in this therapeutic modality.Objectives: To investigate factors associated with 30-day perioperative complications (POC) after aorto-
iliac (AI) stenting, and to compare follow-up cardiovascular prognosis between patients with and
without POC.
Materials and methods: This was a retrospective multicenter study. We used a multicenter database of 2012
consecutive patients who successfully underwent AI stenting for peripheral arterial disease in 18 centers in Japan
from January 2005 to December 2009 to analyze independent predictors of POC and impact of POC on prognosis
by logistic regression and a Cox proportional hazard regression model, respectively.
Results: Mean age was 71  9 years (median: 72 years; range: 37e98 years), and 1,636 patients (81%) were
men. POC occurred in 126 patients (6.3%). In multivariate logistic regression analysis, old age (80 years),
critical limb ischemia (CLI), and Trans Atlantic Inter-Societal Consensus (TASC) II class C/D were independently
associated with POC with adjusted odds ratios and 95% conﬁdence intervals (CI) of 1.9 (1.3e2.9), 2.3 (1.5e3.4),
and 2.4 (1.6e3.4), respectively. Out of 2012 patients, 1995 were followed up for more than 30 days (mean:
2.6  1.5 years; range: 2e2,393 days). In a Cox hazard regression model adjusted for baseline clinical
characteristics, POC was positively and independently associated with follow-up major adverse cardiac events
(adjusted hazard ratio [HR]: 1.9; 95% CI: 1.3e2.8; p ¼ .002), but not with major adverse limb events and target
lesion revascularization (adjusted HR: 1.4; 95% CI: 0.7e2.7; p ¼ .25; and adjusted HR: 1.2; 95% CI 0.6e2.6;
p ¼ .568), respectively.rresponding author. O. Iida, Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, Hyogo 660-8511, Japan.
il address: iida.osa@gmail.com (O. Iida).
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132 O. Iida et al.Conclusions: Age >80 years, CLI, and TASC C/D lesion were positively associated with POC after AI stenting.
Occurrence of POC appears to adversely affect follow-up cardiovascular, but not limb and vessel prognosis.
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For localized (Trans Atlantic Inter-Societal Consensus [TASC]
A/B) aorto-iliac occlusive disease (AIOD), stenting is
considered the treatment of choice with high technical
success rate1 and acceptable durability thanks to recent
device improvements and increased operator experience.2,3
Extensive (TASC C/D) AIOD also is treated with stent-
supported endovascular therapy (EVT) depending on site
and operator experience, and studies have documented
encouraging durability and low procedural mortality rates.4
Although in the latter setting the long-term primary patency
rate cannot yet compete with that reported for open
reconstruction surgery, primary patency loss is predomi-
nantly treated by repeat EVT achieving secondary patency
rates of 80e90%, which appear comparable to those of
surgical bypass therapy.5,6 Moreover, from the recent
covered versus balloon expandable stent trial (COBEST)
trial, covered stents perform better for TASC C and D lesions
than bare stents in terms of longer-term patency and clin-
ical outcome.7 Because a wide range has been reported for
rates of perioperative complications (POC) after stent-based
AIOD treatment likely secondary to heterogeneity in tech-
niques, devices, study populations, and comorbidities, we
investigated clinical factors associated with 30-day POC af-
ter aorto-iliac (AI) stenting and assessed impact of POC on
mid-term cardiovascular outcomes.METHODS
Study population
This study enrolled consecutive patients who underwent
stent placement for de novo atherosclerotic AI lesions in 18
centers in Japan from January 2005 to December 2009. In
all participating centers in this study, AI disease was deﬁned
as arterial lesions spanning from the juxtarenal aorta to the
external iliac artery (Fig. 1). Exclusion criteria have been
reported previously7 as (1) asymptomatic or with unknown
symptoms before procedure (n ¼ 53); (2) treatment with
angioplasty alone (n ¼ 161); (3) restenotic lesions
(n ¼ 125); (4) lesions secondary to radiation or dissection
(n ¼ 0); (5) history of lower extremity bypass surgery or EVT
(n ¼ 169); (6) acute onset limb ischemia (n ¼ 0); (7) failed
endovascular revascularization (n ¼ 51); or (8) inadequate
data (n ¼ 84). Clinical factors associated with 30-day POC
after AI stenting and impact of POC on follow-up prognosis
were assessed in an overall population of 2012 consecutive
patients who successfully underwent AI stenting and
completed 30-day POC assessment. The study protocol was
designed in accordance with the Declaration of Helsinki,
approved by the ethics committee of each participating
hospital, and registered with the University HospitalMedical Information Network-Clinical Trial Registry
(UMIN000006032). All patients provided written informed
consent.Interventional procedure
Indication and strategy for endovascular procedure were
decided by consensus among consulting vascular specialists,
including vascular surgeons and interventional radiologists,
based on ﬁndings in computed tomography or duplex ul-
trasound prior to diagnostic angiography of the lower limb.
EVT was performed by an interventional radiologist at all
centers but one, which reﬂects the fact that the vast ma-
jority of cardiac and peripheral vascular procedures in Japan
are done by interventional cardiologists and radiologists.
Indication of revascularization for AIOD included lesions
with >50% diameter stenosis assessed by angiography and
mean pressure gradient >10 mmHg evaluated by a 4-Fr
diagnostic catheter. The EVT approach and stent selection
were decided by the operators based on anatomical fea-
tures. In general, for AIOD stenotic lesions, a 6-F sheath was
inserted retrogradely through a femoral access, and
5,000 units of unfractionated heparin were injected intra-
arterially. A 0.035- or 0.014-inch wire was advanced into
the lesion, and the stent was directly deployed followed by
dilation of an optimally sized balloon for 60 seconds. For
totally occlusive lesions, a bi-directional approach, namely
antegradely from brachial artery and retrogradely from
ipsilateral femoral artery, was regularly used for recanali-
zation and the intraluminal approach was generally used,
with the subintimal approach with the wire loop technique
being reserved for cases of failed wire-crossing. Re-entry
devices were not approved for use in Japan at the time of
the study. After successful wire-crossing of chronic total
occlusion (CTO) lesions, direct stenting with encouraging
angioplasty was done for prevention of distal embolization
and vessel perforation based on each individual site’s
interventional experience. Post-procedure, the Angioseal
STS PLUS (St. Jude Medical, St Paul, MN, USA) closure de-
vice was employed whenever possible. Iso-osmolar contrast
medium was used during procedures with inconsistent use
among centers of low osmolarity contrast medium. Dual
antiplatelet therapy (aspirin 100 mg/d and cilostazol
200 mg/d, or ticlopidine 200 mg/d) was started at least 1
week prior to EVT and continued until follow up comple-
tion; clopidogrel was not approved for use in Japan at the
time of study onset. All patients were followed up at 1 and
4 weeks, and every 3 months thereafter. Duplex ultrasound
and ankle-brachial index (ABI) assessment for restenosis
were routinely conducted at follow-up. The decision for
target lesion revascularization (TLR) was clinically driven by
recurrent symptoms and by angiographic assessment.
Figure 1. Representative case of aorto-iliac (AI) disease before and after stenting. Upper panel shows Trans Atlantic Inter-Societal
Consensus (TASC) A common iliac artery (CIA) stenosis. Balloon-expandable stent was deployed. Lower panel shows TASC D AI occlu-
sion. Balloon-expandable stents were implanted from aorta to CIA and self-expandable stents were implanted from CIA to external iliac
artery.
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The deﬁnitions of lower limb severity and the criteria for
diagnosis of atherosclerosis risk factors have been reported
previously.7 Worsening of renal function was deﬁned as
recurring transient hemodialysis or increase in creatinine
level >0.2 (mg/dL). Coronary artery disease (CAD) and
cerebrovascular disease (CVD) was deﬁned as presence of
symptoms or past history of infarction or history of any
revascularization. Myocardial infarction (MI) was deﬁned as
signiﬁcant elevation of levels of serum biomarkers
(troponin T > 0.1 ng/ml or twice normal creatine kinase
level) or new Q waves on electrocardiogram. Stroke was
deﬁned as cerebral stroke that persisted for at least 24
hours with neurological deﬁcit. Critical limb ischemia (CLI)
was deﬁned as presence of chronic ischemic rest pain with
ankle pressure <50 mmHg or toe pressure <30 mmHg, or
ulcers or gangrene with ankle pressure <70 mmHg or toe
systolic pressure <50 mmHg attributable to objectively
proven chronically arterial occlusive disease in accordance
with European Society for Vascular Surgery guidelines.8
Major adverse cardiovascular events (MACE) included all-
cause death, MI, and stroke. Major adverse limb events
(MALE) were deﬁned as major amputation or any major re-
intervention during the study period. Major re-interventionincluded new bypass graft, jump, interposition graft
revision, or the use of thrombectomy or thrombolysis in
stents upon loss of primary assisted patency. Minor re-
intervention was deﬁned as endovascular procedures
(percutaneous transluminal angioplasty, atherectomy, and
stenting) without thrombectomy or thrombolysis, and mi-
nor surgical revisions (patch angioplasty). Major amputa-
tion was deﬁned as above-ankle amputation. Any
amputation at or distal to the Lisfranc level was not
considered a limb salvage failure. Data on each event were
obtained through outpatient clinic follow-up contact. Pri-
mary patency was deﬁned as treated lesions without
restenosis/reocclusion, as assessed by angiography or
duplex ultrasound. TLR was deﬁned as re-intervention for
>50% diameter stenosis identiﬁed by angiography within
5 mm of the target lesion after documentation of recurrent
clinical symptoms of peripheral artery disease (PAD).
Main outcomes
Main study outcomes were predictors of POC by logistic
regression analysis. Additionally, a Cox proportional model
was used to assess impact of POC on clinical outcomes,
including MACE, cardiovascular events, all-cause death, MI,
and stroke as patient-related outcomes; MALE and major
Table 1. Perioperative complications at 30 days.
Variables %, n 6.3 (126/2012)
Death 0.3 (7)
Myocardial infarction 0.2 (3)
Stroke 0.4 (7)
Worsening of renal function 0.9 (17)
Intestinal bleeding 0.2 (4)
Stent thrombosis 0.3 (6)
Pseudoaneurysm 0.3 (6)
Vessel perforation 0.2 (4)
Distal embolization 1.6 (32)
Puncture site hematoma 1.6 (33)
Others 0.3 (7)
134 O. Iida et al.amputation as limb-related outcomes; and TLR and primary
patency as vessel-related outcomes.Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS, Chicago, IL, USA). Data are shown as means and SD
for continuous variables or as percentages for dichotomous
variables, unless otherwise mentioned. Between-group
differences in continuous or dichotomous variables were
evaluated by the unpaired t test or Fisher’s exact test,
respectively. Statistical signiﬁcance level was set at p <.05.Table 2. Baseline characteristics.
Variables %, n POC (þ), n ¼ 126
Patient characteristics
Age, y 74  9
Age > 80 y 30 (38)
Male gender 79 (99)
BMI, kg/m2 21  4
BMI < 18.5 15 (19)
Hypertension 81 (102)
Dyslipidemia 41 (52)
Diabetes mellitus 52 (65)
Regular dialysis 19 (24)
CAD 46 (58)
CVD 31 (39)
Heart failure 14 (18)
Ejection fraction <40% 10 (13)
Lower limb characteristics
Rutherford criteria (1/2/3/4/5/6) 6 (7)/19 (24)/41 (52)/19
(24)/13 (16)/2 (3)
Critical limb ischemia 34 (43)
ABI at baseline 0.53  0.28
Lesion characteristics
TASC classiﬁcation (A/B/C/D) 28 (35)/27 (34)/17 (22)/28
TASC C and D 45 (57)
CTO 35 (44)
Lesion length, mm 60  36
RVD, mm 7.9  1.1
% diameter stenosis (pre-/post-) 90  11 (50e100)/7  12
Lesion calciﬁcation 59 (74)
Femoral lesions 41 (52)
Outﬂow lesions 48 (61)
Note. BMI ¼ body mass index; CAD ¼ coronary artery disease; CVD ¼
Atlantic Inter-Societal Consensus; CTO ¼ chronic total occlusion; RVDIndependent POC predictors were determined by multi-
variate logistic regression analysis using two multivariate
models for each outcome: one into which all signiﬁcant
explanatory variables in univariate models were entered
(model 1), and another into which variables were entered
using a stepwise method (model 2). Data are presented as
odds ratios (OR) and their 95% conﬁdence intervals (CI).
Risk stratiﬁcation of POC was based on groupings by
number of risk factors. Impact of POC on prognostic out-
comes was analyzed by the KaplaneMeier method and the
Cox proportional hazard regression model. Hazard ratios
(HR) are reported with their 95% CI.
RESULTS
POC
Overall, POC within 30 days were documented in 6.3%
(126/2012) of patients (Table 1). Death occurred in seven
(0.3%) patients during the perioperative period. MI, stroke,
and intestinal bleeding occurred in 0.2% (three), 0.4%
(seven), and 0.2% (four), respectively. Post-procedural
worsening of renal function was documented in seven-
teen (0.9%) patients. Distal embolism and vessel perfora-
tion, which are life- and limb-threatening complications
during an endovascular procedure for AIOD lesions, were
observed in 33 (1.6%) and four (0.2%) patients, respectively,POC (), n ¼ 1886 p
71  9 <.0001
14 (270) <.0001
81 (1537) .42
22  3 .0057
13 (241) .46
81 (1524) .97
45 (843) .45
48 (899) .39
18 (333) .69
51 (953) .60
23 (428) .03
12 (218) .36
9 (113) .73
8 (146)/30 (570)/47 (878)/7
(141)/6 (122)/2 (29)
<.0001
22 (407) <.0001
0.63  0.23 <.0001
(35) 50 (938)/27/(506)/10 (197)/13 (245) <.0001
23 (442) <.0001
22 (407) .0005
51  40 .012
8.1  2.4 .26
(0e50) 87  11 (25e100)/5  11 (0e75) .005/.06
51 (968) .11
31 (585) .02
35 (666) .0030
cerebrovascular disease; ABI ¼ ankle-brachial index; TASC ¼ Trans
¼ reference vessel diameter.
Figure 2. Occurrence of perioperative complications according to
the number of risk factors. Perioperative complications (POC)
occurred in 126/2012 (6.3%) of patients. Risk factors for POC were
old age (>80 years), critical limb ischemia, and Trans Atlantic Inter-
Societal Consensus (TASC) C or D lesion (see Table 3). According to
number of risk factors for POC, incidence of POC was higher in the
higher score groups (0: 3% [36/1085]; 1: 7% [49/677]; 2: 14% [30/
207]; 3: 26% [11/43]).
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observed in 39/2012 (1.9%) patients. Of the 1.6% of pa-
tients who developed puncture site hematoma, all
managed without surgical repair, but required transfusion.
Pseudoaneurysm was observed in six (0.3%) patients.
Within 30 days, stent thrombosis occurred in six (0.3%)
patients.
Baseline characteristics of patients with and without POC
Comparison of baseline characteristics between patients
with and without POC is shown in Table 2. Mean age was
higher (74  9 years vs. 71  9 years; p < .0001) and body
mass index was lower (21  4 vs. 22  3; p < .0001) in the
POC (þ) group than in the POC () group. In terms of risk
factors and comorbidities, there were no signiﬁcant differ-
ences except for frequency of patients with CVD (31% vs.
23%; p ¼ .03). Compared with the POC () group, the POC
(þ) group had higher prevalence of patients with critical
limb ischemia (34% vs. 22%: p < .0001), and lower ABI at
baseline (0.53  0.28% vs. 0.63  0.23: p < .0001),Table 3. Predictors of perioperative complications after multivariable
Univariate model
Unadjusted OR (95% CI)
Age > 80 y 2.2 (1.5, 3.3)**
Male gender 0.8 (0.5, 1.3)
BMI < 18.5 kg/m2 1.2 (0.7, 2.0)
Diabetes mellitus 1.2 (0.8, 1.7)
Hypertension 1.0 (0.6, 1.6)
Hyperlipidemia 0.8 (0.5, 1.1)
Regular dialysis 1.1 (0.7, 1.7)
Cardiovascular disease 1.2 (0.8, 1.7)
Critical limb ischemia 2.8 (1.9, 4.2)**
TASC C or D 2.7 (1.9, 3.9)**
Femoral lesion 1.6 (1.1, 2.3)*
Below the knee lesion 1.9 (1.2, 3.1)**
Note. Data are odds ratios (OR) and their 95% conﬁdence intervals (
Consensus.*p < .05, **p < .01.suggestive of more severe limb status. Regarding baseline
lesion characteristics, there was a higher prevalence of TASC
C/D lesions (45% vs. 23%: p < .0001), with longer mean
lesion length (60  36 mm vs. 51  40 mm; p ¼ .012), and
higher prevalence of CTO (35% vs. 22%; p ¼ .0005) and
outﬂow lesions (48% vs. 35%; p ¼ .003).
Independent predictors for POC and risk stratiﬁcation
Predictors of POC by multivariable analysis using a logistic
regression model are shown in Table 3. Age >80 years (OR,
1.9; 95% CI, 1.3e2.9; p < .01), critical limb ischemia (OR,
2.3; 95% CI, 1.5e3.4; p < .01), and TASC C/D (OR, 2.4; 95%
CI, 1.6e3.4; p < .01) were positively associated with POC.
Fig. 2 shows risk stratiﬁcation of POC according to number
of these risk factors. POC incidence was higher in the higher
score groups.
Prognostic impact of POC on follow-up outcomes
Prognostic impact of POC on follow-up outcomes is shown
in Table 4. Mean and median follow-up period was
2.6  1.5 and 2.4 years (range, 2e2393 days), respectively.
After multivariate Cox proportional hazard regression
analysis, POC was positively and independently associated
with follow-up MACE (adjusted HR, 1.9; 95% CI, 1.3e2.8;
p ¼ .002) and cardiovascular events (adjusted HR, 2.5; 95%
CI, 1.6e4.0; p < .001). Fig. 3 shows the impact of POC on
MACE up to 5 years. Freedom from MACE was higher in the
POC () group than in the POC (þ) group up to 5 years
(56.8  8.0% vs. 76.5  1.7%, p < .001). In univariate Cox
proportional hazard regression analysis, POC occurrence
had the strongest impact on incidence of major amputation
(adjusted HR, 5.6; 95% CI, 1.8e17.0; p ¼ .003), but this was
not entered into the multivariate model because of an
insufﬁcient number of events for multivariate analysis.
Impact of POC on incidence of major amputation is shown
in Fig. 4. Freedom from major amputation was higher in the
POC () group than in the POC (þ) group up to 5 years
(96.3  1.8% vs. 99.1  0.3%; p ¼ .001). The adjusted HR
for MALE and TLR was 1.4 (0.7e2.7; p ¼ .254) and 1.2 (0.6e
2.6; p ¼ .568), respectively. During follow-up, surgicalanalysis by logistic regression model.
Multivariate model 1
Adjusted OR (95% CI)
Multivariate model 2
Adjusted OR (95% CI)
1.9 (1.3, 2.9)** 1.9 (1.3, 2.9)**
e e
e e
e e
e e
e e
e e
e e
2.0 (1.3, 3.2)** 2.3 (1.5, 3.4)**
2.4 (1.6, 3.4)** 2.4 (1.6, 3.4)**
1.1 (0.8, 1.7) e
1.3 (0.7, 2.2) e
CI). BMI ¼ body mass index; TASC ¼ Trans Atlantic Inter-Societal
Table 4. Hazard ratio (HR) of perioperative complications for various future outcomes.
Outcome measure (number of
observed events)
Univariate model
Unadjusted HR [95% CI] (p)
Multivariate model 1a
Adjusted HR [95% CI] (p)
Multivariate model 2b
Adjusted HR [95% CI] (p)
Per patient
MACE (285) 2.2 [1.5, 3.3] (<0.001) 2.0 [1.3, 2.9] (.001) 1.9 [1.3, 2.8] (.002)
Cardiovascular event (168) 3.0 [1.9, 4.6] (<.001) 2.7 [1.7, 4.2] (<.001) 2.5 [1.6, 4.0] (<.001)
All-cause death (224) 1.8 [1.1, 2.8] (.017) 1.5 [0.9, 2.4] (.105) 1.4 [0.9, 2.2] (.181)
Cardiovascular death (97) 2.4 [1.3, 4.6] (.005) 2.1 [1.1, 3.9] (.028) e
Myocardial infarction (44) 3.5 [1.6, 7.9] (.002) 3.4 [1.5, 7.8] (.004) e
Stroke (66) 3.5 [1.8, 6.8] (<.001) 3.3 [1.7, 6.6] (.001) e
Per limb
MALE (148) 1.5 [0.8, 2.8] (.186) 1.5 [0.8, 2.7] (.223) 1.4 [0.7, 2.7] (.254)
Major amputation (17) 5.6 [1.8, 17] (.003) e e
Per lesion
Surgical re-intervention (28) 2.2 [0.7, 7.4] (.191) e e
Any re-intervention (133) 1.2 [0.6, 2.5] (.604) 1.2 [0.6, 2.5] (.581) 1.2 [0.6, 2.6] (.568)
Primary patency (306) 1.3 [0.9, 2.1] (.200) 1.3 [0.8, 2.1] (.266) 1.3 [0.8, 2.0] (.298)
Note. Data are adjusted HR and their 95% conﬁdence intervals (CI). “e” indicates that multivariate analysis was not performed owing to an
insufﬁcient number of events (relative to the number of explanatory variables). MACE ¼ major adverse cardiovascular events;
MALE ¼ major adverse limb events.*p < 0.05, **p < 0.01.
a Multivariate model 1: adjusted for age 80 y, critical limb ischemia (CLI), and Trans Atlantic Inter-Societal Consensus (TASC) C/D (risk
factors for perioperative complications).
b Multivariate model 2: adjusted for age 80 y, CLI, and TASC C/D, as well as gender, body mass index <18.5 kg/m2, diabetes mellitus,
hypertension, hyperlipidemia, regular dialysis, history of cardiovascular disease, femoral lesion, and below-the-knee lesion.
136 O. Iida et al.revascularization was performed for 28 patients (1.3%),
including 15 who received treatment for restenosis (re-
obstruction), eight who underwent femoropopliteal bypass
surgery as additional treatment to improve symptoms, two
who received endoatherectomy, and three who received
treatment for a new lesion. This a relatively low proportionFigure 3. Impact of perioperative complications (POC) on major
adverse cardiovascular events (MACE). Freedom from MACE was
higher in the POC () group than in POC (þ) group up to 5 years
(56.8  8.0% vs. 76.5  1.7%; p < .001).of post-EVT surgical revascularization, thereby unlikely to
sizably bias EVT outcome interpretation.
DISCUSSION
According to the latest 2013 American College of Cardiol-
ogy/American Heart Association guidelines,3 stenting is
effective as the primary therapy for both stenosis andFigure 4. Impact of perioperative complications (POC) on incidence
of major amputation. Freedom from major amputation was higher
in the POC () group than in POC (þ) group up to 5 years
(96.3  1.8% vs. 99.1  0.3%; p ¼ .001).
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dence level 1 and class B. For severe AIOD, including TASC II
C and D lesions, surgical bypass therapy has been used as a
ﬁrst-line therapy because of its reliable durability.2,9 How-
ever, EVT with stenting is widely used for these lesions
because of relatively acceptable durability, albeit lower than
that for surgery, and low procedural mortality in the clinical
setting. Although patency after AIOD stenting has been
investigated as a primary outcome measure, POC rate,
especially in this era of device and technique advances in
endovascular therapy, has not been systematically exam-
ined. Therefore, it is clinically important to deﬁne future
occurrence of POC and its clinical impact on outcomes to
inform decision making on EVT strategy.
In this study, among PAD patients treated with AI stent-
ing, incidence of POC increased with greater severity of
patient, limb, and lesion status. This appears to be the case
across vascular treatment options, including percutaneous
coronary intervention (PCI) and major vascular surgery. For
instance, in this era of elective PCI for patients with CAD,
coronary perforation, a life-threatening complication, is
associated with complex lesions leading to higher occur-
rence of acute and long-term major adverse cardiac
events.10 An adverse impact of perioperative bleeding on
prognosis also has been reported in patients with acute
coronary syndrome.11 After major vascular surgery, patients
with major complications have a higher mortality rate and
prolonged hospitalization.12,13 In contrast, risk stratiﬁcation
of POC and its clinical impact on prognosis after AI stenting
has not been well examined. To the best of our knowledge
this is the ﬁrst study on risk factor-based stratiﬁcation of
POC occurrence and evaluation of association between POC
and clinical outcomes following stent-supported EVT for
patients with PAD presenting with AIOD. In earlier studies,
heterogeneity in baseline characteristics of PAD patients
with AIOD, endovascular devices used, and operator expe-
rience likely underlies the variation in complication rates
reported. Our results are based on more homogeneous
distributions of these variables and, consequently, should
provide greater reliability to inform decision making of EVT
strategy.
In terms of associations between POC and clinical out-
comes, POC independently inﬂuenced incidence of MACE
and cardiovascular events. However, MALE as limb-related
endpoint, and TLR and primary patency as vessel-related
endpoints were not independently associated with POC.
However, in univariate analysis, POC showed a strong
impact on follow-up occurrence of major amputation,
especially during the early phase after EVT (Fig. 3). There
was an insufﬁcient number of patients with major ampu-
tation to perform multivariate analysis; however, POC
would be expected to affect the major amputation rate
after EVT in patients with AIOD. In terms of patient-related
clinical outcomes, POC did not affect overall survival, even
though it was associated with incidence of MACE, as well as
cardiovascular events and cardiovascular death. To explain
the latter observation, one might hypothesize that POC
might lead to anemia or untoward hemodynamic changes,in turn underlying cardiovascular ischemia that negatively
affected only patients with CAD and CVD. The impact of a
restrictive strategy of red cell transfusion on short-term
mortality was reported for intensive care unit (ICU) patients
with a hemoglobin concentration of no more than 9.0 g/dL
within 72 hours of ICU admission;14 however, further
investigation is needed to assess the impact of anemia on
clinical outcomes after AI stenting.
Because of acceptable durability, albeit not as high as
that for open surgery,9 low procedural mortality, device
improvement, and increased operator experience, stent-
supported EVT is widely used in clinical practice. In light
of the association between POC occurrence and clinical
outcomes documented in this study, stratiﬁcation based on
number of risk factors for POC occurrence plays an impor-
tant role in decision making in this therapeutic modality.
The ﬁndings of this study, however, are limited by the
retrospective nature of the analysis of only endovascular
procedural and clinical data, despite the inclusion of a large
number of patients form multiple centers. Also, new-
generation stents, especially covered stents were not used
in this study population. A recent trial reported that
covered stents play an important role in obtaining accept-
able patency and low complication rates.5,15 Therefore,
further investigation is needed with covered stents and
POC. Finally, there was not a universal protocol for anti-
platelet therapy use among participating centers, which
precludes appropriate analysis of the effect of adjunctive
pharmacotherapy in the context of POC. In particular, the
role of dual antiplatelet therapy (DAPT) should be studied
because cardiovascular events regularly occur in patients
with PAD; whether the beneﬁts of DAPT supersede its risk
remains unclear.
CONCLUSION
Age >80 years, CLI, and TASC C/D lesion were positively
associated with POC after successful AI stenting. Occurrence
of POC appears to adversely affect follow-up cardiovascular,
but not limb and vessel, prognosis.
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